Skip to Main Content

Third Harmonic Bio has launched from stealth mode with $155 million to develop a single therapy that the Cambridge, Mass., startup hopes can treat multiple diseases caused by severe allergies and inflammation.

The experimental drug, which is in early clinical studies to test its safety, came from a set of molecules that the company licensed from pharmaceutical giant Novartis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment